All posts by: Michael Zand

About Michael Zand

Bristol-Myers Bets Nearly $2B on Nektar for an Immunotherapy Boost – Xconomy

Continue reading

2018-02-14 NEWS

Xconomy

Bristol-Myers Bets Nearly $2B on Nektar for an Immunotherapy Boost
Xconomy
When it comes to spending cash on potential combinations for its cancer immunotherapy drugs, Bristol-Myers Squibb (NYSE: BMY) isn’t afraid of the b-word: billions. The New York-based pharma firm is paying Nektar Therapeutics (NASDAQ: NKTR) of San
Bristol, needing a cancer immunotherapy boost, pays shockingly steep price for Nektar drugSTAT
Why Bristol-Myers Squibb just made a $1.85 billion bet on a cancer drugBusiness Insider
Record-smashing $3.6 billion deal propels SF drug company in cancer immunotherapy packSan Francisco Business Times
Science Magazine (blog) –Genetic Engineering & Biotechnology News –WHTC
all 205 news articles »
Continue reading

2018-02-14 NEWS

Technology Networks

Lonza to Establish Cell- and GeneTherapy Centers of Excellence to Accelerate Growth
Technology Networks
Lonza will establish Centers of Excellence for Cell and Gene Therapy to support and accelerate the growth of this priority area for the company. This decision advances Lonza’s strategy of being one of the world’s leading, integrated, value-added

and more »

Continue reading

2018-02-14 NEWS

Technology Networks

Lonza to Establish Cell- and Gene-Therapy Centers of Excellence to …
Technology Networks
Lonza will establish Centers of Excellence for Cell and Gene Therapy to support and accelerate the growth of this priority area for the company. This decision advances Lonza’s strategy of being one of the world’s leading, integrated, value-added
Lonza to establish cell and gene therapy centres of excellenceEPM Magazine

all 2 news articles »

Continue reading

2018-02-14 NEWS

Technology Networks

Lonza to Establish Cell- and GeneTherapy Centers of Excellence to Accelerate Growth
Technology Networks
Lonza will establish Centers of Excellence for Cell and Gene Therapy to support and accelerate the growth of this priority area for the company. This decision advances Lonza’s strategy of being one of the world’s leading, integrated, value-added

and more »